Segment Reporting - Reconciliation of Net Loss to Adjusted EBITDA (Loss), Discontinued Operations (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Reconciliation of Net Loss from Discontinued Operations, net of tax to Adjusted EBITDA from Discontinued Operations
Net loss from discontinued operations, net of tax	$ (14,185)	$ (5,355)	$ (58,905)	$ (18,484)
Loss on divestiture of business			2,879
Adjusted EBITDA (loss) from discontinued operations	(3,593)	2,578	(1,036)	7,294
DoseMe, SinfonaRx and PrescribeWellness businesses | Discontinued Operations, Held-for-sale or Disposed of by Sale
Reconciliation of Net Loss from Discontinued Operations, net of tax to Adjusted EBITDA from Discontinued Operations
Net loss from discontinued operations, net of tax	(14,185)		(58,905)
Income tax (benefit) expense	(94)		(662)
Depreciation and amortization			7,331
Impairment charges	5,845		42,293
Loss on divestiture of business	2,879		2,879
Settlement			1,448
Divestiture-related expense	104		216
Stock-based compensation expense	1,858		4,364
Adjusted EBITDA (loss) from discontinued operations	$ (3,593)		$ (1,036)
DoseMe, SinfonaRx and PrescribeWellness businesses | Discontinued Operations, Held-for-sale
Reconciliation of Net Loss from Discontinued Operations, net of tax to Adjusted EBITDA from Discontinued Operations
Net loss from discontinued operations, net of tax		(5,355)		(18,484)
Income tax (benefit) expense		52		182
Depreciation and amortization		6,771		20,234
Settlement				500
Stock-based compensation expense		1,110		4,862
Adjusted EBITDA (loss) from discontinued operations		$ 2,578		$ 7,294